




Intracerebral Hemorrhage and Exposure to Antithrombotic Drugs
Nielsen, Peter Brønnum; Milling, Truman J.; Lip, Gregory Y.H.
Published in:
JAMA NETWORK OPEN







Publisher's PDF, also known as Version of record
Link to publication from Aalborg University
Citation for published version (APA):
Nielsen, P. B., Milling, T. J., & Lip, G. Y. H. (2021). Intracerebral Hemorrhage and Exposure to Antithrombotic
Drugs. JAMA NETWORK OPEN, 4(5), [e219175]. https://doi.org/10.1001/jamanetworkopen.2021.9175
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            ? Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            ? You may not further distribute the material or use it for any profit-making activity or commercial gain
            ? You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to
the work immediately and investigate your claim.
Downloaded from vbn.aau.dk on: August 24, 2021
Invited Commentary | Neurology
Intracerebral Hemorrhage and Exposure to Antithrombotic Drugs
Peter Brønnum Nielsen, PhD, MPH; Truman J. Milling, MD; Gregory Y. H. Lip, MD
Intracerebral hemorrhage (ICH) is a devastating clinical manifestation of bleeding into the brain
parenchyma from a ruptured arterial vessel, and antithrombotics are known to be associated with
worse ICH outcomes. Among patients with, for example, atrial fibrillation or venous
thromboembolism, we accept this increased bleeding risk because the known reduction in
thrombosis, such as stroke, far outweighs it. Despite the net benefit, during the warfarin era, only half
of the patients who should have been undergoing anticoagulation actually were.1 Thus, we hoped
that direct oral anticoagulants (DOACs), thought to be safer drugs might make inroads into this
undertreated population. To achieve much greater stroke and other thrombosis prevention, we had
to accept that risk of bleeding, including more ICH events, might worsen somewhat.
In this issue of JAMA Network Open, the findings of Hald et al2 are reassuring in this regard
because they found that despite increased use of anticoagulants, largely driven by DOAC use, ICH
prevalence has not increased in a Danish population. Hald et al2 investigated associations between
exposure to antithrombotic drugs and subsequent odds of ICH among Danish residents. Using a
case-control study design, they identified cases as individuals with an incident ICH diagnosis
obtained from a dedicated stroke registry. The control population was sampled from Danish
residents free of ICH, thus exploiting the strengths of risk set sampling, and controls were matched
with cases by age, sex, and calendar year. Among 16765 case patients, incident ICH was significantly
associated with antithrombotic use compared with matched controls. The strongest association was
found among users of vitamin K antagonists (odds ratio [OR], 2.76; 95% CI, 2.58-2.96).
Epidemiologic studies3,4 have suggested that the strongest clinical risk factor associated with
ICH is hypertension, but psychosocial factors and lifestyle (in particular alcohol abuse) have been
reported to be more prevalent among patients who present with ICH. Although antithrombotic
treatment is known to be associated with ICH, the medication itself is unlikely to be the cause of the
ICH. However, concurrent antithrombotic treatment is a modifiable risk factor for hematoma
expansion and thus crucial to identify early to mitigate poor outcomes. Indeed, ICH risk can be
assessed using bleeding risk scores, such as the HAS-BLED score (hypertension, abnormal renal and
liver function, stroke, bleeding, labile international normalized ratio, elderly, and drugs or alcohol),
although such scores should be appropriately used to flag modifiable bleeding risk factors to mitigate
harm and to schedule patients at high risk for bleeding for early review and follow-up.5 An integrated
and holistic patient approach has been shown in the prospective mobile atrial fibrillation application
II trial in which intervention with the ABC (Atrial fibrillation Better Care) pathway, with proactive use
of the HAS-BLED score, was associated with less major bleeding and an increase in oral
anticoagulation use compared with usual care.6
The provided evidence from Hald et al2 on the strength of the association between
antithrombotic use and ICH carries little clinical value in terms of how best to approach patients who
present with an ICH. We already know, for example, that patients with ICH and atrial fibrillation are
at high risk for subsequent ischemic stroke and death, but the immediate concern is that of recurrent
bleeding. Obviously, clinical factors determining the indication for antithrombotic use is of key
importance because the treatment has been initiated to prevent ischemia, including ischemic stroke.
In confined analyses that focused on patients with atrial fibrillation or venous
thromboembolism as an indication for antithrombotic treatment, the results generally reflected
those of the main analyses. However, among dabigatran users, the risk of ICH was lower than among
those who never used antithrombotic drugs (OR, 0.80; 95% CI, 0.56-1.13). Clearly, this is
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counterintuitive despite an expected class effect of DOACs having a relative low risk of ICH compared
with warfarin.7 A similar and potentially spurious association was observed when using warfarin as
the reference group to compare the risk of ICH with the use of rivaroxaban (OR, 1.20; 95% CI,
1.03-1.41), which again challenges the expected class effect of DOACs with the lower risk of ICH
compared with warfarin.7 These results highlight that the evidence provided should not be used to
guide clinical practice.
Nevertheless, the study presents a compelling overview of the landscape of ICH during the past
few decades and confirms that antithrombotic use has a rare but potentially devastating adverse
effect. However, despite increased use, particularly of DOACs, the incidence of ICH has not increased,
suggesting that a net benefit is maintained at a population level. Prospective randomized clinical
trials are needed to better define and expand the patient population that may benefit from
anticoagulation, including those reinitiating anticoagulation who sustain an ICH. Of note,
nontraumatic ICH may differ from traumatic ICH in the risk of subsequent ischemic and bleeding
events; hence, a specific trial on restarting anticoagulation after traumatic ICH is planned.8
Nontraumatic ICH is more complicated, depending on site of the bleed and other imaging features,
such as the presence of multiple microbleeds. Patients with nontraumatic ICH require an integrated
care approach, including input from stroke neurologists, cardiologists, neurosurgeons, primary care
physicians, and the patient.
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